CLEC2D and rheumatoid arthritis: This large-scale study involving various randomised clinical trials and international research collaborations yielded eight novel pharmacogenetic loci for TCZ treatment response in RA, which includes SNPs in the coding region of GALNT18 (rs4910008), ENOX1 (rs9594987), CLEC2D (rs1560011), CD69 (rs11052877), KCNMB1 (rs703505) and SLC9A7 (rs7055107) genes, as well as the rs10108210 and rs703297 (non-gene) variants.